Amorfix receives ISO13485 certification

    TSX Venture: AMF

    - Completes step toward commercialization of vCJD diagnostic test -

    TORONTO, June 15 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company
focused on diagnostics and treatments for brain wasting diseases, today
announced that it has achieved ISO13485:2003 certification for its in vitro
diagnostic EP-vCJDTM test for detection of aggregated misfolded proteins in
variant Creutzfeldt-Jacob Disease (vCJD).
    "This achievement is a significant step forward in the commercialization
of our proprietary EP-vCJD(TM) diagnostic test for screening blood donations,"
said Dr. George Adams, CEO of Amorfix Life Sciences. "The ISO certification
demonstrates we have the processes needed to manufacture and distribute the
test to the international quality standards required by customers. We are on
schedule to obtain a European Union CE mark and launch our first product in
the first quarter of 2008."

    ISO Certification

    ISO13485:2003 is an internationally recognized process-based quality
management system standard for medical devices developed by the International
Organization for Standardization. ISO13485 specifies requirements for a
Quality Management System which demonstrate the organization's ability to
provide medical devices and related services that consistently meet customer
and applicable regulatory requirements. The management systems that are
essential include staff training, customer and regulatory communication,
product design and development, sourcing and purchasing of materials and
services, and delivery of products and services.

    About Amorfix

    Amorfix is an emerging theranostics company focused on the diagnosis and
treatment of brain-wasting diseases, where aggregated misfolded proteins
(AMPs) are prevalent. These include "prions", the infectious agents of the
Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD,
as well as degenerative diseases such as Alzheimer's Disease, ALS and
Parkinson's Disease. Amorfix is focused on discovering and commercializing
technologies to become the world leader on AMP diseases. The company will use
this knowledge to develop diagnostic kits, treatments and vaccines for AMP

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information. Such information
involves known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs as well
as assumptions made by and information currently available to it as well as
other factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890